<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04779216</url>
  </required_header>
  <id_info>
    <org_study_id>2020P000329</org_study_id>
    <nct_id>NCT04779216</nct_id>
  </id_info>
  <brief_title>Effects of Romosozumab on Bone Density in Women With Anorexia Nervosa</brief_title>
  <official_title>Effects of Romosozumab on Bone Density, Markers of Bone Metabolism and Bone Microarchitecture in Women With Anorexia Nervosa: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karen Klahr Miller, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This protocol is a randomized, double-blind, placebo-controlled clinical trial which aims to&#xD;
      investigate the effect of romosozumab on BMD in women with anorexia nervosa. The&#xD;
      investigators will also investigate the safety of romosozumab in women with anorexia nervosa.&#xD;
      The investigators hypothesize that 12 months of romosozumab administration will result in an&#xD;
      increase in bone mineral density, increase in markers of bone formation and decrease in&#xD;
      markers of bone resorption, and improvement in bone microarchitecture in osteopenic women&#xD;
      with anorexia nervosa compared with placebo.&#xD;
&#xD;
      The extension study will offer subjects 12-month administration of open-label alendronate (an&#xD;
      oral bisphosphonate) 70 mg once weekly after the initial 12 month administration of&#xD;
      romosozumab or placebo. The investigators hypothesize that 12 months of romosozumab followed&#xD;
      by 12 months of open-label alendronate will result in a greater increase in BMD compared to&#xD;
      12 months of placebo followed by 12 months of open-label alendronate. Within the group of&#xD;
      women who receive sequential therapy with 12 months of romosozumab followed by 12 months of&#xD;
      alendronate, the investigators hypothesize that BMD will be maintained between 12 and 24&#xD;
      months while on alendronate.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 20, 2021</start_date>
  <completion_date type="Anticipated">January 2025</completion_date>
  <primary_completion_date type="Anticipated">January 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double Blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in bone density</measure>
    <time_frame>12 months</time_frame>
    <description>Change in bone density</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in bone density</measure>
    <time_frame>6 months, 24 months</time_frame>
    <description>Change in bone density</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Bone Density, Low</condition>
  <condition>Bone Loss</condition>
  <condition>Anorexia Nervosa</condition>
  <condition>Eating Disorders</condition>
  <arm_group>
    <arm_group_label>Active Romosozumab 210mg Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Romosozumab 210mg injection monthly for 12 months. Alendronate 70mg PO weekly starting at Month 12 through 24 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo injection monthly for 12 months. Alendronate 70mg PO weekly starting at Month 12 through 24 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Romosozumab Prefilled Syringe</intervention_name>
    <description>Romosozumab 210mg Injection monthly for 12 months</description>
    <arm_group_label>Active Romosozumab 210mg Injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo Injection monthly for 12 months</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alendronate 70Mg Tab</intervention_name>
    <description>Alendronate 70mg PO weekly starting at 12 months through 24 months.</description>
    <arm_group_label>Active Romosozumab 210mg Injection</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female&#xD;
&#xD;
          -  Age 20-60 years, skeletally mature with closed epiphyses&#xD;
&#xD;
          -  Anorexia nervosa or atypical anorexia nervosa defined by DSM-V diagnostic criteria&#xD;
&#xD;
          -  BMD T-score &lt; -1.0&#xD;
&#xD;
          -  Normal serum 25-OH vitamin D (&gt;30 ng/mL) and calcium levels&#xD;
&#xD;
          -  For women of reproductive age, agree to use an effective contraceptive method. Highly&#xD;
             effective methods of birth control include: combined (estrogen and progestogen)&#xD;
             hormonal methods (pills, vaginal ring, or skin patch), intrauterine device (IUD),&#xD;
             intrauterine hormonal-releasing system (IUS), surgery to tie both fallopian tubes&#xD;
             (bilateral tubal ligation/occlusion), and woman's male partner has had a vasectomy and&#xD;
             testing shows there is no sperm in the semen&#xD;
&#xD;
          -  Dental check-up within the past year&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Body mass index (BMI) &lt;17 kg/m2&#xD;
&#xD;
          -  Hospitalization within 3 months of baseline study visit, including inpatient eating&#xD;
             disorder treatment facility; participating in a residential eating disorder treatment&#xD;
             program within 3 months of study participation is permitted&#xD;
&#xD;
          -  Myocardial infarction or stroke within 1 year preceding enrollment&#xD;
&#xD;
          -  Any disease known to affect bone, including untreated thyroid dysfunction, Cushing's&#xD;
             or renal failure&#xD;
&#xD;
          -  Any medication known to affect bone metabolism within 3 months of the study, excluding&#xD;
             oral contraceptives or other forms of estrogen administration. Bisphosphonates must&#xD;
             have been discontinued for at least one year before participation&#xD;
&#xD;
          -  Immunodeficiency or taking immunosuppressive therapy&#xD;
&#xD;
          -  Serum 25-OH vitamin D level &lt;30 ng/mL&#xD;
&#xD;
          -  Serum potassium &lt;3.0 meq/L&#xD;
&#xD;
          -  Serum magnesium &lt;1.5 meq/L&#xD;
&#xD;
          -  Serum ALT &gt;3 times upper limit of normal&#xD;
&#xD;
          -  eGFR of less than 30 ml/min&#xD;
&#xD;
          -  LDL &gt; 190 mg/dL&#xD;
&#xD;
          -  Hypocalcemia&#xD;
&#xD;
          -  Diabetes mellitus&#xD;
&#xD;
          -  Active substance abuse, including alcohol&#xD;
&#xD;
          -  History of malignancy&#xD;
&#xD;
          -  Paget disease of bone&#xD;
&#xD;
          -  Osteomalacia&#xD;
&#xD;
          -  Osteonecrosis of the jaw (ONJ) or risk factor for ONJ, such as invasive dental&#xD;
             procedures (eg, tooth extraction, dental implants, oral surgery in the past 6 months),&#xD;
             poor oral hygiene, periodontal and/or pre-existing dental disease, and current use of&#xD;
             corticosteroids&#xD;
&#xD;
          -  Planned invasive dental procedure over the next 24 months&#xD;
&#xD;
          -  Known sensitivity to any of the products or components of the medication to be&#xD;
             administered&#xD;
&#xD;
          -  Sensitivity to calcium or vitamin D supplements&#xD;
&#xD;
          -  Pregnant, planning to become pregnant within 7 months after the end of treatment,&#xD;
             and/or breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Karen K Miller, MD</last_name>
    <phone>617-726-3870</phone>
    <email>kkmiller@mgh.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Erinne Meenaghan, NP</last_name>
    <phone>617-724-7393</phone>
    <email>emeenaghan@mgh.harvard.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen K Miller, MD</last_name>
      <phone>617-724-3870</phone>
      <email>kkmiller@mgh.harvard.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 26, 2021</study_first_submitted>
  <study_first_submitted_qc>February 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2021</study_first_posted>
  <last_update_submitted>September 20, 2021</last_update_submitted>
  <last_update_submitted_qc>September 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Karen Klahr Miller, MD</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bone Diseases, Metabolic</mesh_term>
    <mesh_term>Anorexia</mesh_term>
    <mesh_term>Feeding and Eating Disorders</mesh_term>
    <mesh_term>Anorexia Nervosa</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alendronate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

